Solid Biosciences received clearance by the U.S. FDA for an Investigational New Drug (IND) application for SGT-003 for DMD 

See the last Solid Biosciences announcement HERE

Research News: Solid Biosciences received clearance by the U.S. FDA for an Investigational New Drug application for SGT-003, their next generation microdystrophin gene therapy candidate for the treatment of Duchenne. With this clearance, Solid is planning to submit the study for IRB approval at their clinical sites and expects to commence patient screening shortly thereafter.

The clinical study, termed INSPIRE DUCHENNE, is a Phase 1/2 multicenter clinical trial to primarily evaluate the safety and tolerability of SGT-003, beginning with patients 4 and 5 years old.

Read more in their:
Letter to the community HERE
READ THE FULL PRESS RELEASE HERE